Recent studies demonstrate that genotype-guided antiplatelet strategies can reduce ischemic events in CYP2C19 loss of function allele carriers without increasing bleeding risk, while allowing safe de-escalation to clopidogrel in noncarriers. Join a multidisciplinary panel of experts to discuss the clinical challenges of DAPT in PCI, evidence for gene-guided therapy, and case-based strategies for implementing rapid genetic testing. At the end of this activity, participants will be able to: 1. Explain the impact of CYP2C19 genetic variants on clopidogrel efficacy and thrombotic risk. 2. Evaluate the risks of high versus low platelet reactivity and in individualized DAPT selection. 3. Appraise key clinical trials and current guideline and consensus recommendations for CYP2C19 testing in PCI. 4. Implement appropriate antiplatelet therapy de-escalation or escalation.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Member | Free |
| Non-Member | $19 |
| Fellow-In-Training | Free |
| Cardio Team Member | Free |
Collected from the provider’s public pages · source
- No reviews yet. Be the first to share yours.



